Usefulness of cardiac biomarkers for prognosis of better outcomes in chronic heart failure: Retrospective 18-year follow-up study.
Age Factors
Aged
Aged, 80 and over
Biomarkers
Blood Pressure
Body Weight
C-Reactive Protein
/ analysis
Chronic Disease
Comorbidity
Female
Follow-Up Studies
Heart Failure
/ blood
Heart Rate
Heat-Shock Proteins
/ blood
Hematologic Tests
Humans
Male
Middle Aged
Natriuretic Peptide, Brain
/ blood
Peptide Fragments
/ blood
Peroxidase
/ blood
Retrospective Studies
Sex Factors
Ventricular Function, Left
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
05 Feb 2021
05 Feb 2021
Historique:
received:
07
07
2020
accepted:
02
11
2020
entrez:
17
2
2021
pubmed:
18
2
2021
medline:
4
3
2021
Statut:
ppublish
Résumé
Brain natriuretic peptide is an established, surrogate follow-up marker, strongly correlated with heart failure severity. Several other biomarkers and tests are useful for assessing the prognosis of patients with HF, such as oxidized low-density lipoprotein antibodies and C-reactive protein. Some inflammatory cells, including monocytes, lymphocytes, and neutrophils, are involved in coronary heart disease and may be useful for prognosis also. This study assessed the potential usefulness of various laboratory biomarkers in predicting long-term outcomes and hospitalization among a cohort of outpatients with chronic, advanced HF.This retrospective, 18-year follow-up study included all patients admitted to the Heart Failure Outpatient Unit in our tertiary care medical center from 2000 through 2001 due to chronic HF. Excluded were patients with malignant disease, severe stroke, active inflammatory disease, or infection. At the first visit, blood was sampled for routine analysis and biomarkers NT-proBNP, C-reactive protein, myeloperoxidase, heat shock protein, and antibodies to oxidized low density lipoprotein. left ventricular ejection fraction and New York Heart Association class class were also established. Patients were followed every 3 months. Study endpoints were mortality or first hospitalization.Among 305 study patients, HF duration ranged from 2 months to 18 years. Mean follow-up was 9.1 ± 6 years. Mean time to first hospitalization was 60 ± 58.1 months, median = 38 (range 0-179). Mortality rate was 41%. Regression analysis showed New York Heart Association class, lymphocyte count and alkaline phosphatase were independent predictors of survival, with hazard ratios of 1.0, 0.973, and 1.006, respectively (P < .05).N-terminal pro-B-type natriuretic peptide, alkaline phosphatase, and lymphocyte count are important prognostic predictors for very long-term follow-up among patients with chronic HF.
Identifiants
pubmed: 33592824
doi: 10.1097/MD.0000000000023464
pii: 00005792-202102050-00011
pmc: PMC7870268
doi:
Substances chimiques
Biomarkers
0
Heat-Shock Proteins
0
Peptide Fragments
0
pro-brain natriuretic peptide (1-76)
0
Natriuretic Peptide, Brain
114471-18-0
C-Reactive Protein
9007-41-4
Peroxidase
EC 1.11.1.7
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e23464Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Bui A, Horwich T, Fonarow G. Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011;8:30–41.
Naylor S. Biomarkers: current perspectives and future prospects. Expert Rev Mol Diagn 2003;3:525–9.
Shahid F, Lip GYH, Shantsila E. Role of monocytes in heart failure and atrial fibrillation. J Am Heart Assoc 2018;7:e007849.
Wrigley BJ, Shantsila E, Tapp LD, et al. CD14++CD16+ monocytes in patients with acute ischaemic heart failure. Eur J Clin Invest 2013;43:121–30.
Gillum RF, Mussolino ME, Madans JH. Counts of neutrophils, lymphocytes, and monocytes, cause-specific mortality and coronary heart disease: the NHANES-I epidemiologic follow-up study. Ann Epidemiol 2005;15:266–71.
Prentice RL, Szatrowski TP, Fujikura T, et al. Leukocyte counts and coronary heart disease in a Japanese cohort. Am J Epidemiol 1982;116:496–509.
Umemoto S, Suzuki N, Fujii K, et al. Eosinophil counts and plasma fibrinogen in patients with vasospastic angina pectoris. Am J Cardiol 2000;85:715–9.
Batista M, Santos R, Lopes R, et al. Endurance training modulates lymphocyte function in rats with post-MI CHF. Med Sci Sport Excer 2008;40:549–56.
Avanzas P, Quiles J, Lopez de Sa E, et al. Neutrophil count and infarct size in patients with acute myocardial infarction. Int J Cardiol 2004;97:155–6.
Madjid M, Fatemi O. Components of the complete blood count as risk predictors for coronary heart disease: in-depth review and update. Tex Heart Inst J 2013;40:17–29.
Biasucci LM, D’Onofrio G, Liuzzo G, et al. Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. J Am Coll Cardiol 1996;27:611–6.
Wheeler JG, Mussolino ME, Gillum RF, et al. Associations between differential leucocyte count and incident coronary heart disease: 1764 incident cases from seven prospective studies of 30,374 individuals. Eur Heart J 2004;25:1287–92.
Nasir K, Guallar E, Navas-Acien A, et al. Relationship of monocyte count and peripheral arterial disease: results from the national health and nutrition examination survey 1999-2002. Arterioscler Thromb Vasc Biol 2005;25:1966–71.
Grau AJ, Boddy AW, Dukovic DA, et al. Leukocyte count as an independent predictor of recurrent ischemic events. Stroke 2004;35:1147–52.
Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and effect of valsartan. Circulation 2005;112:1428–34.
Li Z, Song Y, Xing R, et al. Heat shock protein 70 acts as a potential biomarker for early diagnosis of heart failure. PLoS One 2013;8:e67964.
D’Onofrio G, Mancini R, Vallone R, et al. Acquired myeloperoxidase deficiency: an indicator of subclinical activation of blood coagulation? Blood Cells 1983;9:455–64.
Singal PK, Kapur N, Dhillon KS, et al. Role of free radicals in catecholamine-induced cardiomyopathy. Can J Physiol Pharmacol 1982;60:1390–7.
Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 1996;28:506–14.
George J, Wexler D, Roth A, et al. Usefulness of anti-oxidized LDL antibody determination for assessment of clinical control in patients with heart failure. Eur J Heart Fail 2006;8:58–62.
Charach G, George J, Afek A, et al. Antibodies to oxidized LDL as predictors of morbidity and mortality in patients with chronic heart failure. J Card Fail 2009;15:770–4.
Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (Val-HeFT). Circulation 2003;107:1278–83.
Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013;62:263–71.
McMurray J, Chopra M, Abdullah I, et al. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 1993;14:1493–8.
Wright SP, Doughty RN, Pearl A, et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol 2003;42:1793–800.
Charach G, Grosskopf I, Roth A, et al. Usefulness of total lymphocyte count as predictor of outcome in patients with chronic heart failure. Am J Cardiol 2011;107:1353–6.
Holvoet P, Mertens A, Verhamme P, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001;21:844–8.
Tsutsui T, Tsutamoto T, Wada A, et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol 2002;39:957–62.
Steinerova A, Racek J, Stozicky F, et al. Antibodies against oxidized LDL- theory and clinical use. Physiol Res 2001;50:131–41.